Recent years have seen the role of a biopharma industry leader alter drastically, with events like the COVID-19 pandemic and the war in Ukraine reshaping the day-to-day operations of the sector, from drug distribution to the dominance of remote working. In Vivo caught up with six leaders across the space – from big pharma to generics and biosimilars developers – to get their take on the changing role of a biopharma industry leader.
Matt Gline, CEO of growing biotech company Roivant Sciences Ltd., said: “That’s a hard question and I still spend...